Comparing the Efficacy of Articaine and Lignocaine in Maxillary Irreversible Pulpitis: A Randomized Triple Blind Study

Introduction: Effective pain control during endodontic treatment is a mandatory component of patient care. The most commonly used anesthetic agent is lignocaine. Aims & Objectives: The objective of this study is to compare the efficacy of Articaine and Lignocaine in maxillary irreversible pulpitis cases in terms of pain management. Place and Duration of Study: The study was conducted in the outpatient department of Operatives Dentistry, Azra Naheed Dental College, The Superior University Lahore, Pakistan during 2023. Material & Method: The present study is a triple-blind, randomized controlled trial in which 75 patients were selected by non-probability sampling. Patients were randomized into Group A and Group B. For both groups, the drugs were delivered using a standard aspirating syringe with a sterile single-use 27G 0.40 X 21mm disposable dental needle. For buccal vestibular local infiltration, the drug was administered at the buccal vestibule supra periosteal adjacent to the tooth to be endodontically treated at a rate of approximately 1ml. Ethical approval was taken from the IRB. Data was analyzed through SPSS version 24. Results: A significant difference in anesthetic effect between 4% Articaine and 2% Lignocaine following an infiltration injection for maxillary first molars with irreversible pulpitis was found with a p-value of <0.001. Conclusion: 4% Articaine is more efficacious than 2% lignocaine in irreversible pulpitis cases and can be used to produce desired analgesic effect.